The identification of new biomarkers to guide diagnosis, treatment, and risk stratification represents nowadays a growing and promising research field. Namely, many hematological diseases and post-allogeneic stem cell transplant (SCT) complications still lack an easy tool to allow early diagnosis, grading, and follow-up.
An ideal biomarker should be non-invasive, easily measured, inexpensive, and produce rapid results. Moreover, it should have a high sensitivity, allowing early detection, and no overlap in values between diseased patients and healthy controls. Furthermore, it should have high specificity and possess prognostic value in terms of real outcomes. When compared with traditional biopsies, liquid biopsy markers, such as circulating cells, circulating cell-free DNA, and extracellular vesicles, are considered more convenient and less invasive, furthermore, they are easier to perform also in fragile patients. MiRNAs are a class of molecules that have attracted a lot of attention in recent years. Their involvement in many pathophysiologic processes is reflected by numerous studies showing that they could serve as markers. Finally, efforts in genomics, proteomics, and metabolomics could potentially lead to the discovery of new biomarkers with better specificity and sensibility.
The goal of this research topic is to publish current research related to the discovery, use, and limitation of novel biomarkers that could have a role in hematological diseases and in SCT complications (such as complications of endothelial origin like graft versus host disease, transplant-associated thrombotic microangiopathy, and sinusoidal obstruction syndrome).
We welcome submissions of Review, Mini-Review, Opinion, as well as Original Research articles focusing on, but not strictly limited to the following topics:
1) Identification and validation of biomarkers involved in complications of allogeneic cell transplant and hematological diseases (examples complications of endothelial origin)
2) Discovery of new biomarkers for accurate risk stratification and Minimal disease monitoring
3) Role of old and new biomarkers in surveillance, diagnosis, prognosis, and prediction of response in different hematological diseases, both oncologic and not oncologic
4) Outcome biomarkers of allogeneic cell transplant and hematological diseases
5) Prospective evaluation of biomarkers for precision medicine and personalized medicine
6) Biomarker’s identification and validation for possible theranostic strategies
7) cell-based, gene-based, and protein-based key liquid biopsy markers
8) Extracellular vesicles
9) miRNAs
10) cell-free DNA
11) genomics, proteomics, metabolomics
12) Cytokines
The identification of new biomarkers to guide diagnosis, treatment, and risk stratification represents nowadays a growing and promising research field. Namely, many hematological diseases and post-allogeneic stem cell transplant (SCT) complications still lack an easy tool to allow early diagnosis, grading, and follow-up.
An ideal biomarker should be non-invasive, easily measured, inexpensive, and produce rapid results. Moreover, it should have a high sensitivity, allowing early detection, and no overlap in values between diseased patients and healthy controls. Furthermore, it should have high specificity and possess prognostic value in terms of real outcomes. When compared with traditional biopsies, liquid biopsy markers, such as circulating cells, circulating cell-free DNA, and extracellular vesicles, are considered more convenient and less invasive, furthermore, they are easier to perform also in fragile patients. MiRNAs are a class of molecules that have attracted a lot of attention in recent years. Their involvement in many pathophysiologic processes is reflected by numerous studies showing that they could serve as markers. Finally, efforts in genomics, proteomics, and metabolomics could potentially lead to the discovery of new biomarkers with better specificity and sensibility.
The goal of this research topic is to publish current research related to the discovery, use, and limitation of novel biomarkers that could have a role in hematological diseases and in SCT complications (such as complications of endothelial origin like graft versus host disease, transplant-associated thrombotic microangiopathy, and sinusoidal obstruction syndrome).
We welcome submissions of Review, Mini-Review, Opinion, as well as Original Research articles focusing on, but not strictly limited to the following topics:
1) Identification and validation of biomarkers involved in complications of allogeneic cell transplant and hematological diseases (examples complications of endothelial origin)
2) Discovery of new biomarkers for accurate risk stratification and Minimal disease monitoring
3) Role of old and new biomarkers in surveillance, diagnosis, prognosis, and prediction of response in different hematological diseases, both oncologic and not oncologic
4) Outcome biomarkers of allogeneic cell transplant and hematological diseases
5) Prospective evaluation of biomarkers for precision medicine and personalized medicine
6) Biomarker’s identification and validation for possible theranostic strategies
7) cell-based, gene-based, and protein-based key liquid biopsy markers
8) Extracellular vesicles
9) miRNAs
10) cell-free DNA
11) genomics, proteomics, metabolomics
12) Cytokines
